Clinical trial

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

NCT06422403

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-11-25

PhasePHASE2

Study timeline

Study start (actual)2024-11-25Date precision: day

Registry last updated2025-01-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Hepatocellularunresolved

Gastric Adenocarcinomaunresolved

GastroEsophageal Cancerunresolved

Oesophageal Cancerunresolved

Non-small Cell Lung Cancerunresolved

Head and Neck Squamous Cell Carcinomaunresolved

Interventions

Extended Dosing Interval - ADRUG

Extended Dosing Interval - BDRUG

Extended Dosing Interval - CDRUG

Standard of Care - ADRUG

Standard of Care - BDRUG

Standard of Care - CDRUG

Sponsors & collaborators

National University Hospital, Singaporelead sponsor

Mapped research locations

SingaporeSingapore1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06422403 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.